Related references
Note: Only part of the references are listed.9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19
Shayan Riahi et al.
ENDOCRINE RESEARCH (2021)
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min et al.
DIABETES THERAPY (2021)
Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry
Clemens Kamrath et al.
LANCET CHILD & ADOLESCENT HEALTH (2021)
Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes
Yunha Noh et al.
DIABETES CARE (2021)
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Julie Dubourg et al.
DIABETES CARE (2021)
Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis
Kasper B. Kristensen et al.
DIABETOLOGIA (2021)
Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
Ana Rita de Oliveira dos Santos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
Matthias von Herrath et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Qiu Wang et al.
DIABETES THERAPY (2021)
Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways
Mingyan Yao et al.
FRONTIERS IN MEDICINE (2021)
The promising future of insulin therapy in diabetes mellitus
Ran Cheng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2021)
Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: A German claims data analysis
Maximilian Gabler et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Hiddo J. L. Heerspink et al.
EUROPEAN HEART JOURNAL (2021)
The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review
Moein Zangiabadian et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors
Yi-Hsin Chan et al.
DIABETES OBESITY & METABOLISM (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie et al.
JAMA INTERNAL MEDICINE (2021)
Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial
Jens Christian Laursen et al.
ECLINICALMEDICINE (2021)
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes
Bart Keymeulen et al.
DIABETOLOGIA (2021)
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease
Soie Kwon et al.
DIABETES CARE (2020)
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
W. Timothy Garvey et al.
DIABETES CARE (2020)
Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis
Pan Luo et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
Celestino Sardu et al.
DIABETES CARE (2020)
Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies
Dawit Zewdu Wondafrash et al.
JOURNAL OF DIABETES RESEARCH (2020)
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
Sebastiano Bruno Solerte et al.
ACTA DIABETOLOGICA (2020)
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
Manjunath Krishnappa et al.
CARDIOVASCULAR DIABETOLOGY (2020)
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Sanjay Kalra et al.
DIABETES THERAPY (2020)
Drug Delivery System in the Treatment of Diabetes Mellitus
Ruichen Zhao et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Elena Carboni et al.
MEDICAL HYPOTHESES (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Julio Rosenstock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control
Magdalene K. Montgomery et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Prevalence of Gestational Diabetes in India by Individual Socioeconomic, Demographic, and Clinical Factors
Goutham Swaminathan et al.
JAMA NETWORK OPEN (2020)
Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
2,3,5,6-Tetramethylpyrazine improves diet-induced whole-body insulin resistance via suppressing white adipose tissue lipolysis in mice
Yuyao Xiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Therapeutic siRNA: state of the art
Bo Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Effects of metformin in obesity treatment in different populations: a meta-analysis
Ruiyang Pu et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
Guidelines for the prevention and management of diabetic retinopathy and diabetic eye disease in India: A synopsis
Clare Gilbert et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2020)
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Rajeev Chawla et al.
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES (2020)
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Raffaella Gentilella et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
The efficacy of metformin compared with insulin in regulating blood glucose levels during gestational diabetes mellitus: A randomized clinical trial
Nayereh Ghomian et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
Erin S. Morgan et al.
DIABETES CARE (2019)
Premix insulins in type 1 diabetes: the coming of degludec/aspart
Marc Rendell
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the thorough QT/QTc study (Q-SET study)
S. Erande et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Insulin Pumps: Review of Technological Advancement in Diabetes Management
Nicoleta D. Sora et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Major Advances and Discoveries in Diabetes-2019 in Review
Juleen R. Zierath
CURRENT DIABETES REPORTS (2019)
Tetramethylpyrazine prevents diabetes by activating PI3K/Akt/GLUT-4 signalling in animal model of type-2 diabetes
Uddipak Rai et al.
LIFE SCIENCES (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia
Pitchai Balakumar et al.
CURRENT MOLECULAR PHARMACOLOGY (2019)
GLP-2 Analogues as First Specific Treatment of Intestinal Failure
Irina Blumenstein
VISCERAL MEDICINE (2019)
Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
John White et al.
JOURNAL OF PHARMACY TECHNOLOGY (2019)
Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Fahmida Alam et al.
SCIENTIFIC REPORTS (2019)
SANRA-a scale for the quality assessment of narrative review articles
Christopher Baethge et al.
RESEARCH INTEGRITY AND PEER REVIEW (2019)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
Prevalence of Diagnosed Diabetes in Adults by Diabetes Type - United States, 2016
Kai McKeever Bullard et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
Maja Danic et al.
FRONTIERS IN PHARMACOLOGY (2018)
Implications of Removing Rosiglitazone’s Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes
Ryan P. Hickson et al.
Journal of Managed Care & Specialty Pharmacy (2018)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum
William T. Cefalu et al.
DIABETES CARE (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing
Lisa Schlender et al.
BMC GERIATRICS (2017)
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
Arun Chaudhury et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion
Jinquan Cai et al.
DIABETES CARE (2016)
Effects of Piragliatin, a Glucokinase Activator, on Fasting and Postprandial Plasma Glucose in Patients With Type 2 Diabetes Mellitus
Jianguo Zhi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report
Sarayu A. Pai et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An Overview of Insulin Pumps and Glucose Sensors for the Generalist
Brooke H. McAdams et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Renal safety of newer medications
Amar Puttanna et al.
PRACTICAL DIABETES (2016)
Sulfonylureas and their use in clinical practice
Daniele Sola et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Enrique Z. Fisman et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus
Zhi-Xu He et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Insulin resistance in brain alters dopamine turnover and causes behavioral disorders
Andre Kleinridders et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A Me Too'' or the Special One'' Antidiabetic Class?
Ricardo Godinho et al.
JOURNAL OF DIABETES RESEARCH (2015)
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study
David M. Nathan
LANCET DIABETES & ENDOCRINOLOGY (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells
Per-Ola Carlsson et al.
DIABETES (2015)
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis
Richard M. Turner et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone
Anil Pareek et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
David M. Nathan
DIABETES CARE (2014)
Diagnosis and Classification of Diabetes Mellitus
DIABETES CARE (2014)
Metformin-mode of action and clinical implications for diabetes and cancer
Ida Pernicova et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Insulin Receptor Signaling in Normal and Insulin-Resistant States
Jeremie Boucher et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
Y. Onishi et al.
DIABETES OBESITY & METABOLISM (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
Miyako Kishimoto
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2013)
α-Glucosidase inhibitors and their use in clinical practice
Giuseppe Derosa et al.
ARCHIVES OF MEDICAL SCIENCE (2012)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
V. Pirags et al.
DIABETES OBESITY & METABOLISM (2012)
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Harold E. Lebovitz
DIABETES CARE (2011)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Protective effect of tetramethylpyrazine isolated from Ligusticum chuanxiong on nephropathy in rats with streptozotocin-induced diabetes
Qi-Hong Yang et al.
PHYTOMEDICINE (2011)
Challenges in drug discovery for thiazolidinedione substitute
Jian-ping Ye
ACTA PHARMACEUTICA SINICA B (2011)
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
J. Michael Gaziano et al.
DIABETES CARE (2010)
The rise and fall of rosiglitazone
Steven E. Nissen
EUROPEAN HEART JOURNAL (2010)
Immunologic endocrine disorders
Aaron W. Michels et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus
Hiroyuki Konya et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
Ronald B. Goldberg et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25-LAP+ T cells
Hirofumi Ochi et al.
NATURE MEDICINE (2006)
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
JL Chiasson et al.
LANCET (2002)
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
KC Herold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control
C Weyer et al.
CURRENT PHARMACEUTICAL DESIGN (2001)
Share Paper
